×
About 7,030 results

ALLMedicine™ Follicular Lymphoma Center

Research & Reviews  2,056 results

Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for ...
https://doi.org/10.1007/s12185-022-03363-3 10.1158/1535-7163.MCT-12-1182 10.1182/blood-2009-06-225979 10.1007/s12325-016-0451-1 10.1056/NEJMoa1614598 10.1007/s12185-018-2497-0 10.1016/S0140-6736(12)61763-2 10.1182/blood-2013-11-531327 10.1007/s00277-016-2668-0 10.1634/theoncologist.2017-0037 10.1007/s12185-016-2146-4 10.2169/internalmedicine.9628-17 10.1111/bcp.13920
International Journal of Hematology; Fujiwara Y, Urata T et. al.

May 19th, 2022 - Progression-free survival in patients with untreated follicular lymphoma (FL) has significantly improved with obinutuzumab plus chemotherapy followed by obinutuzumab maintenance, compared with rituximab plus chemotherapy. However, the survival out...

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03789240

May 13th, 2022 - Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin s lymphoma (NHL) with a highly variable clinical course across patients Standard frontline therapy for FL includes a monoclonal anti-CD20 antibody with or without chemoth...

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05371093

May 12th, 2022 - Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up ass...

Loss of RARRES1 function Promotes Follicular Lymphomagenesis and Inhibits B cell Differ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066096
International Journal of Biological Sciences; Patel J, Xun D et. al.

May 12th, 2022 - Retinoic acid receptor responder 1 (RARRES1) is among the most commonly methylated loci in multiple cancers. RARRES1 regulates mitochondrial and fatty acid metabolism, stem cell differentiation, and survival of immortalized cell lines in vitro. He...

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients ...
https://doi.org/10.1182/bloodadvances.2021006520
Blood Advances; Stathis A, Mey UJM et. al.

May 11th, 2022 - This phase I study evaluated safety, tolerability and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two dose levels of venetocl...

see more →

Guidelines  9 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for...
https://doi.org/10.1016/j.annonc.2020.11.008
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Ghielmini M et. al.

Nov 30th, 2020 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Dreyling M,Ghielmini M,Rule S,Salles G,Ladetto M,|therapeutic use,diagnosis,epidemiology,therapy,diagnosis,therapy,the...

The investigation and management of follicular lymphoma.
https://doi.org/10.1111/bjh.16872
British Journal of Haematology; McNamara C, Montoto S et. al.

Jun 25th, 2020 - The investigation and management of follicular lymphoma.|2020|McNamara C,Montoto S,Eyre TA,Ardeshna K,Burton C,|diagnosis,therapy,

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

Non-Hodgkin's lymphomas, version 2.2014.
https://doi.org/10.6004/jnccn.2014.0086
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Jun 14th, 2014 - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for app...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  130 results

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03789240

May 13th, 2022 - Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin s lymphoma (NHL) with a highly variable clinical course across patients Standard frontline therapy for FL includes a monoclonal anti-CD20 antibody with or without chemoth...

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05371093

May 12th, 2022 - Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up ass...

Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03888105

May 10th, 2022 - Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by indepen...

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03817853

May 10th, 2022 - This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with pre...

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len) or Glofitamab + Len With or Without Obinutuzumab; and Evaluating the Safety, Tolerability, and P...
https://clinicaltrials.gov/ct2/show/NCT04246086

May 6th, 2022 - This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab + lenalidomide, glofitamab + lenalidomide, and glofitamab + lenalidomide + obinutuzumab in participants with relapsed or refractory (R/R) follicul...

see more →

News  601 results

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma
https://www.onclive.com/view/match-adjusted-comparison-shows-comparable-efficacy-outcomes-for-axi-cel-and-tisa-cel-in-follicular-lymphoma

Apr 25th, 2022 - Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel (Yescarta; axi-cel) in ZUMA-5 trial (NCT03105336) vs those treated with tisagenlecleucel (Kymriah; tisa-cel) in ELARA (NCT03568461) show...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

see more →

Patient Education  1 results see all →